Company: HURA
Filing Date: 2025-05-06
Form Type: S-4/A
Source: 0001193125-25-113920
Chunk: 534

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-06
Form: S-4/A
Chunk 534
---
 of Prior FY End                                                                 |     |            |          — |   |     |             | — |     |          |          — |   |
| TOTAL ADJUSTMENTS                                                                                                                                                                                         |     |            |   (752,000 | ) |     |             | — |     |          |   (168,000 | ) |

330

| (3) | The dollar amounts reported in column (d) represent the average of the amounts reported for TuHURA’s NEOs as a group (excluding TuHURA’s PEOs) in the “Total” column of the SCT in each applicable year. The names of each of the NEOs included for purposes of calculating the average amounts in each applicable year are as follows: (i) for the years ending December 31, 2024 and 2023, Dan Dearborn and Dennis Yamashita, and (ii) for the year ending June 30, 2023, Dennis Brown (TuHURA’s former Chief Scientific Officer), and Scott Praill (TuHURA’s former Chief Financial Officer). |

| (4) | Cumulative TSR is calculated by dividing the sum of the cumulative amount of dividends for the measurement period, assuming dividend reinvestment, and the difference between TuHURA’s share price at the end and the beginning of the measurement period by TuHURA’s share price at the beginning of the measurement period. The beginning of the measurement period for each year in the table is December 31, 2021. No dividends were paid on stock or option awards in 2022, 2023 or 2024. |

| (5) | The dollar amounts reported represent the amount of net income (loss) reflected in TuHURA’s audited financial statements for (a) the years ending December 31, 2024 and 2023 and (b) the year ending June 30, 2023. |

**Analysis of Information Presented in the Pay Versus Performance Table In accordance with Item 402(v) of Regulation S-K,we are providing the following descriptions of the relationships between information presented in the Pay Versus Performance table above. The following graphs display the CAP to TuHURA’s NEOs compared to TuHURA’s TSR and TuHURA’s net income (loss) for fiscal 2022, 2023 and 2024. TuHURA does not look to net income (loss) as a performance measure for its executive compensation program and instead looks at operational metrics, such as drug